Denali Therapeutics Inc. (DNLI) Earnings History
Annual and quarterly earnings data from 2015 to 2025
Loading earnings history...
DNLI EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
DNLI Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | 100.0% | -59.5% | -43.9% |
| 2022 | 100.0% | -314.2% | -300.6% |
| 2021 | 100.0% | -607.8% | -597.2% |
Download Data
Export DNLI earnings history in CSV or JSON format
Free sign-in required to download data
Denali Therapeutics Inc. (DNLI) Earnings Overview
As of May 8, 2026, Denali Therapeutics Inc. (DNLI) reported trailing twelve-month net income of -$513M, reflecting -15.6% year-over-year growth. The company earned $-2.92 per diluted share over the past four quarters.
Looking at the long-term picture, DNLI's historical earnings data spans multiple years. The company achieved its highest annual net income of $71M in fiscal 2020.
Denali Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PRAX (-$327M net income), ARVN (-$81M net income, -30.8% margin), RCUS (-$369M net income, -142.9% margin), DNLI has comparable earnings metrics. Compare DNLI vs PRAX →
DNLI Earnings vs Peers
Earnings metrics vs comparable public companies
DNLI Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$513M | -21.2% | -$555M | $-2.97 | - | - |
| 2024 | -$423M | -191.1% | -$487M | $-2.57 | - | - |
| 2023 | -$145M | +55.5% | -$197M | $-1.06 | -43.9% | -59.5% |
| 2022 | -$326M | -12.2% | -$341M | $-2.60 | -300.6% | -314.2% |
| 2021 | -$291M | -508.5% | -$296M | $-2.39 | -597.2% | -607.8% |
| 2020 | $71M | +136.0% | $63M | $0.63 | 21.2% | 18.7% |
| 2019 | -$198M | -445.3% | -$213M | $-2.07 | -740.7% | -799.1% |
| 2018 | -$36M | +58.9% | -$46M | $-0.39 | -28.1% | -35.9% |
| 2017 | -$88M | -1.8% | -$90M | $-5.89 | - | - |
| 2016 | -$87M | -416.2% | -$87M | $-13.49 | - | - |
See DNLI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DNLI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DNLI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonDNLI — Frequently Asked Questions
Quick answers to the most common questions about buying DNLI stock.
Is DNLI growing earnings?
DNLI EPS fell to $-2.92, with earnings declining -15.6%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-513M.
What are DNLI's profit margins?
Denali Therapeutics Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are DNLI's earnings?
DNLI earnings data spans 2015-2025. The declining earnings trend is -15.6% YoY. Historical data enables comparison across business cycles.